6 The future and prospects of PYY 6.1 Potential of PYY as a therapeutic target The clinical application of PYY(336) is limited by its short halflife and dosedependent side effects such as nausea and vomiting (156)
Similarly, oral formulations such as orforglipron show high potential for improving adherence, but their safety in humans remains under monitoring (Wharton et al., 2025)
In practice, it seems better to tailor the choice to different patients, depending on the preference of the route of administration (oral vs injectable), the presence of intolerance or side-effects, and contraindications
Sustained Weight Loss Maintenance: The weight loss program at Restorative Health has demonstrated its potential to help individuals maintain their weight loss over the long term
Many insurance plans, employers, and community health organizations offer DPPs at low or no cost